Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. reports developments as a clinical-stage life sciences company focused on rebalancing inflammation with its proprietary formulation Gemini. Company updates center on Gemini programs for acute kidney injury, chronic kidney disease, prevention of post-surgical infection, and severe burn-related hyperinflammation and infection.
Recurring announcements include clinical data from the PRIME study, FDA interactions tied to the AKI development pathway, advisory and conference activity, quarterly financial results, warrant inducement financings, proxy matters, and capital-structure actions such as reverse stock splits and Nasdaq listing compliance matters.
org value="NASDAQ-NMS:REVB"Revelation Biosciences Inc. (NASDAQ: REVB), focused on immunologic-based therapies, announced that CEO James Rolke will join a fireside chat at the 35th Annual Roth Conference from March 12-14, 2023, in location value="LU/us.ca.laguel"Laguna Niguel, California. The chat is scheduled for March 14 at 12:30 p.m. PT in Healthcare - Salon 5. Attendees can access the live webcast via the org value="NASDAQ-NMS:REVB"Revelation website, with a replay available for 30 days. Mr. Rolke will also be available for one-on-one meetings.
Revelation Biosciences Inc. (NASDAQ: REVB) announced the closing of a public offering on February 13, 2023, raising approximately $15.6 million. The offering consisted of 2,888,600 common stock shares and 336,400 pre-funded warrants at $4.83 per share. Additionally, warrants to purchase up to 6,450,000 shares were included, with an exercise price of $5.36. The proceeds will fund clinical studies for REVTx-100 and REVTx-300, focusing on surgical site infections and acute kidney injury. The offering was made under registration statements declared effective on February 9, 2023, by the SEC.
Revelation Biosciences Inc. (NASDAQ: REVB) has announced a public offering of 3,225,000 shares priced at $4.83 each, along with warrants to purchase up to 6,450,000 additional shares at an exercise price of $5.36. The gross proceeds are expected to total approximately $15.6 million, intended for advancing the development of their therapies REVTx-100 and REVTx-300, including clinical trials and manufacturing. The offering is anticipated to close around February 13, 2023, pending usual conditions. Roth Capital Partners serves as the sole placement agent.
Revelation Biosciences Inc. (NASDAQ: REVB) reported statistically significant preclinical results for REVTx-300, a potential therapy for acute and chronic kidney disease. In a validated model, treatment with REVTx-300 led to significant reductions in TGF-β and increases in anti-inflammatory markers IL-10, hepcidin, and NGAL. No significant inflammation markers increased, indicating a potential reduction in fibrosis. The company plans to publish these findings in 2023 and is preparing to initiate clinical studies. Positive results were previously reported on October 25, 2022, and November 18, 2022, regarding renal fibrosis reduction.
Revelation Biosciences Inc. (NASDAQ: REVB) announced a 1-for-35 reverse stock split effective February 1, 2023, after stockholder approval. This action aims to increase the per-share market price to comply with NASDAQ's minimum bid requirements. Consequently, the outstanding shares will decrease to approximately 672,460 shares. Additionally, stockholders approved raising the authorized common stock to 500,000,000 shares and ratified Baker Tilly US, LLP as independent public accountants. The reverse split does not change stockholder equity proportions or the par value of the common stock.
Revelation Biosciences Inc. (NASDAQ: REVB) announced a mandatory separation of its trading units on January 13, 2023. Following this, units will cease to trade on the Nasdaq Capital Market. Each unit, consisting of one common stock share and one warrant priced at $11.50, will convert automatically into shares and warrants. Post-separation, common stock and warrants will trade under the symbols 'REVB' and 'REVBW'. Revelation focuses on immunologic therapies for disease prevention and treatment, with several candidates in development, including REVTx-100, REVTx-200, and REVTx-300.
Revelation Biosciences Inc. (NASDAQ: REVB) announced successful exploratory biomarker analyses supporting the clinical development of REVTx-300 for chronic kidney disease (CKD) and acute kidney injury (AKI). A significant 57% reduction in new collagen deposition was observed in preclinical models, indicating a potential for new intellectual property. Plans include initiating a Phase 1a study in early 2023, followed by a Phase 1b study in patients undergoing cardiac surgery. The CEO emphasized the therapeutic potential of modulating the innate immune response for treating inflammatory diseases.
Revelation Biosciences Inc. (NASDAQ: REVB) reported its third quarter 2022 financial results, highlighting key corporate developments. The company completed a $5.0 million public offering and licensed innovative IP for REVTx-100 aimed at healthcare-associated infections. Notably, positive preclinical data for REVTx-300 in kidney-related conditions was announced. As of September 30, 2022, cash and cash equivalents rose to $6.2 million from $1.3 million in 2021. However, the company recorded a net loss of $1.2 million for Q3 2022, down from $3.0 million in Q3 2021, indicating improved financial performance.
Revelation Biosciences Inc. (NASDAQ: REVB) announced promising preclinical results for REVTx-300, demonstrating a significant reduction in renal cortical fibrosis in models of acute kidney injury (AKI) and chronic kidney disease (CKD). High-dose treatment achieved a reduction of 29.3% (p < 0.05). The company plans to initiate Phase 1 clinical studies in the first half of 2023 and explore additional models including NASH and myocarditis. The findings suggest potential therapeutic benefits for health conditions associated with inflammation.
Revelation Biosciences Inc. (NASDAQ: REVB) announced an exclusive worldwide license with Vanderbilt University to develop phosphorylated hexaacyl disaccharide (PHAD) aimed at treating and preventing infections. The agreement focuses on combatting infections related to surgery, severe burns, and antibiotic resistance. Relevant data reveals approximately 687,000 cases of acquired infections leading to 72,000 deaths annually. Preclinical studies indicate PHAD could enhance innate immune response, potentially shortening infection duration and severity. Revelation also plans to prosecute additional patent applications for further innovations.